Open AccessClinical evidence for a lack of cross-resistance between temsavir and ibalizumab or maraviroc
Author(s) -
Ronald E. Rose,
Margaret Gartland,
Zhufang Li,
Nannan Zhou,
Mark I. Cockett,
Jagadish Beloor,
Max Lataillade,
Peter Ackerman,
Mark Krystal
Publication year - 2021
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000003097
Subject(s) - maraviroc , ccr5 receptor antagonist , entry inhibitor , human immunodeficiency virus (hiv) , pharmacology , biology , virology , chemistry , medicine , genetics , viral replication , virus , viral entry , receptor , chemokine , chemokine receptor
Temsavir (TMR), the active agent of the gp120-directed attachment inhibitor fostemsavir (FTR), the CD4-directed attachment inhibitor ibalizumab (IBA), and the CCR5 antagonist maraviroc (MVC) are antiretroviral agents that target steps in HIV-1 viral entry. Although mechanisms of inhibition of the three agents are different, it is important to understand whether there is potential for cross-resistance between these agents, as all involve interactions with gp120.